Meeting
2019 ASCO Annual Meeting
Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL).
Authors
Stephen Opat
Monash Health, Monash University, Clayton, Victoria, Australia
Stephen Opat , Robert Marcus , Craig Anthony Portell , William Reed , Melannie Co , Jane Huang , Judith Trotman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS7568)
DOI
10.1200/JCO.2019.37.15_suppl.TPS7568
Abstract #
TPS7568
Poster Bd #
321a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.
First Author: Paul Eliezer Oberstein
Poster
2023 ASCO Annual Meeting
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7).
First Author: Brian T. Hess
Poster
2023 ASCO Annual Meeting
waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.
First Author: Pier Luigi Zinzani